Skip to content
Screener

Roivant Sciences ROIV Other Non-Current Assets

Other Non-Current Assets at other companies

Amgen logo
AmgenAMGN
$12.98B+17.7%
Moderna logo
ModernaMRNA
$618M+2,709%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$7.68M+0.8%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$6.38B+7.4%
Regenxbio logo
RegenxbioRGNX
$5.9M+214%
Revvity logo
RevvityRVTY
$322.1M+7.5%

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$25.37B+219%
Enterprise value$25.4B+219%
P/S3,368×+3,026×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q2 2026
Accession
0001635088-26-000090
Line itemJune 30, 2026March 31, 2026
Property and equipment, net11,32011,986
Operating lease right-of-use assets78,88680,416
Investments measured at fair value444,622407,985
Other assets29,58540,916
Total assets$5,306,493$5,708,687
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable$25,084$18,002

Item 1. Financial Statements (Unaudited).

FAQ

What is Roivant Sciences's other non-current assets?
Roivant Sciences (ROIV) reported other non-current assets of $29.59M in Q2 2026.
How has Roivant Sciences's other non-current assets changed year-over-year?
Roivant Sciences's other non-current assets decreased by 4.9% year-over-year, from $31.09M to $29.59M.
What is the long-term trend for Roivant Sciences's other non-current assets?
Over 5 years (2020 to 2025), Roivant Sciences's other non-current assets has grown at a 8.5% compound annual growth rate (CAGR), from $27.2M to $40.92M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about Roivant Sciences's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude